MedPath

AdrenoMed AG

AdrenoMed AG logo
🇩🇪Germany
Ownership
Holding
Established
2009-01-01
Employees
11
Market Cap
-
Website
http://www.adrenomed.com

Clinical Trials

8

Active:3
Completed:5

Trial Phases

2 Phases

Phase 1:4
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (66.7%)
Phase 2
2 (33.3%)

Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB

Phase 2
Completed
Conditions
Septic Shock
First Posted Date
2017-03-21
Last Posted Date
2024-02-21
Lead Sponsor
Adrenomed AG
Target Recruit Count
301
Registration Number
NCT03085758
Locations
🇧🇪

Clinique Universitaire Saint-Luc (UCL Bruxelles), Brussels, Belgium

🇧🇪

Antwerp University Hospital (UZA), Critical Care Medicine, Edegem, Belgium

🇧🇪

Groupe Jolimont, Hospitalier de Jolimont, Haine Saint Paul, Belgium

and more 27 locations

Adrecizumab-LPS Study

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Endotoxin
Drug: Placebo
First Posted Date
2017-03-17
Last Posted Date
2021-02-01
Lead Sponsor
Adrenomed AG
Target Recruit Count
24
Registration Number
NCT03083171
Locations
🇳🇱

Dept. of Intensive Care Medicine, Research-unit, Radboud university medical center, Nijmegen, Gelderland, Netherlands

News

Enibarcimab Shows Promising Results in Biomarker-Guided Septic Shock Treatment

Journal of Critical Care has published positive results from AdrenoMed's Phase II AdrenOSS-2 trial, showing enibarcimab improved organ function and reduced 28-day mortality in septic shock patients.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.